Lynozyfic (linvoseltamab), a bispecific antibody for late-stage multiple myeloma approved last year, sold $16.5 million in Q2 ...

The firms will advance Sail's pipeline of preclinical in vivo CAR T-cell therapies for autoimmune diseases and pursue additional programs.

The firm said NCCN's recommendation in HR-positive breast cancer will drive adoption of the treatment, which it will commercially launch in Q3.

The firm on a call with analysts raised its 2026 full-year revenue guidance, citing growth in new products, including ...

The FDA earlier this month accepted the firm's biological license application for DYNE-251 for the treatment of Duchenne muscular dystrophy.

The partners will conduct preclinical studies to select a lead antisense oligonucleotide candidate therapy for testing in clinical trials.

NEW YORK – The European Medicines Agency has given the green light to an investigator-initiated trial of Lantern Pharma's lead drug candidate LP-184 (zirdafulven) for advanced, recurrent bladder ...

The firm gained approval for one acquired program, the ROS1 inhibitor Jideytro, and is expecting another approval for the ALK inhibitor neladalkib this year.

The company closed an upsized IPO and concurrent private placement to Sanofi, proceeds of which will fund its pipeline of CRISPR-based medicines.

Estrella Immunopharma's first trial of its CD19-directed autologous T-cell therapy for non-Hodgkin's lymphoma is progressing smoothly, the company said late last week, and it has moved on to the dose ...

The firm's oncology unit reported 16 percent growth in Q2, with nearly all oncology medicines reporting revenue growth in the ...